{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-011178","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.337618+00:00","generated_at":"2026-05-23T19:21:23.414465+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CervoMed reports positive Phase 2b extension data for neflamapimod in DLB","bullets":["Neflamapimod slowed clinical progression on CDR-SB vs old capsules (p<0.001) and vs placebo (p=0.003) over 16 weeks.","Mean CDR-SB improvement of 0.73 points with new capsules vs old; 40% relative reduction in clinically meaningful worsening.","Falls incidence reduced to 4% with new capsules vs 15.2% with old (p=0.025) in patients without AD co-pathology.","Improvement also seen on ADCS-CGIC (p=0.035 vs old capsules) and cognitive/fluctuation endpoints.","Company expects to complete full 32-week extension and engage FDA for Phase 3 plans later in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-011178","json":"https://secwatch.observer/filing/0001437749-25-011178.json","markdown":"https://secwatch.observer/filing/0001437749-25-011178.md","text":"https://secwatch.observer/filing/0001437749-25-011178.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925011178/0001437749-25-011178-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925011178/crvo20250407_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:21:23.414465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}